依瑞奈尤单抗治疗伴药物过度使用的慢性偏头痛:随机试验亚组分析
该双盲安慰剂对照研究纳入667例慢性偏头痛成人,按3:2:2随机分配至安慰剂或依瑞奈尤单抗70mg或140mg组,其中41%(n=274)基线符合药物过度使用标准。在药物过度使用亚组中,依瑞奈尤单抗70mg和140mg组第3个月每月偏头痛天数及急性偏头痛特异性药物使用天数降幅均大于安慰剂组,≥50%缓解率更高,患者报告结局也有一致改善。
要点
- 依瑞奈尤单抗70mg和140mg均能减少伴药物过度使用的慢性偏头痛患者的每月偏头痛天数。
- 两剂量均减少急性偏头痛特异性药物使用天数,且≥50%缓解率高于安慰剂。
- 药物过度使用亚组的疗效与非药物过度使用亚组相似。
核心结论
- 依瑞奈尤单抗可降低伴药物过度使用的慢性偏头痛患者的偏头痛频率和急性药物使用天数,并改善残疾与生活质量。
研究设计与样本
- 双盲、安慰剂对照研究,667例慢性偏头痛成人按3:2:2随机分配至安慰剂或依瑞奈尤单抗70mg或140mg组,并按地区和药物过度使用状态分层。
主要发现
- 药物过度使用亚组第3个月每月偏头痛天数变化:依瑞奈尤单抗70mg组均值-6.6(95%CI -8.0至-5.3),140mg组-6.6(95%CI -8.0至-5.3),安慰剂组-3.5(95%CI -4.6至-2.4)。
- 药物过度使用亚组第3个月急性偏头痛特异性药物使用天数变化:70mg组-5.4(95%CI -6.5至-4.4),140mg组-4.9(95%CI -6.0至-3.8),安慰剂组-2.1(95%CI -3.0至-1.2)。
- 药物过度使用亚组≥50%每月偏头痛天数缓解率:安慰剂组18%,70mg组36%(OR 2.67,95%CI 1.36-5.22),140mg组35%(OR 2.51,95%CI 1.28-4.94)。
- 临床反应与患者报告结局改善一致,多个影响、残疾和健康相关生活质量指标均显示依瑞奈尤单抗获益。
- 非药物过度使用亚组观察到的治疗效果与药物过度使用亚组相似。
临床怎么用
- 对于伴药物过度使用的慢性偏头痛患者,可考虑使用依瑞奈尤单抗70mg或140mg以降低偏头痛频率和急性药物使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the effect of erenumab, a human anti-calcitonin gene-related peptide receptor monoclonal antibody, in patients with chronic migraine and medication overuse. METHODS: In this double-blind, placebo-controlled study, 667 adults with chronic migraine were randomized (3:2:2) to placebo or erenumab (70 or 140 mg), stratified by region and medication overuse status. Data from patients with baseline medication overuse at baseline were used to assess changes in monthly migraine days, acute migraine-specific medication treatment days, and proportion of patients achieving ≥50% reduction from baseline in monthly migraine days. RESULTS: Of 667 patients randomized, 41% (n = 274) met medication overuse criteria. In the medication overuse subgroup, erenumab 70 or 140 mg groups had greater reductions than the placebo group at month 3 in monthly migraine days (mean [95% confidence interval] -6.6 [-8.0 to -5.3] and -6.6 [-8.0 to -5.3] vs -3.5 [-4.6 to -2.4]) and acute migraine-specific medication treatment days (-5.4 [-6.5 to -4.4] and -4.9 [-6.0 to -3.8] vs -2.1 [-3.0 to -1.2]). In the placebo and 70 and 140 mg groups, ≥50% reductions in monthly migraine days were achieved by 18%, 36% (odds ratio [95% confidence interval] 2.67 [1.36-5.22]) and 35% (odds ratio 2.51 [1.28-4.94]). These clinical responses paralleled improvements in patient-reported outcomes with a consistent benefit of erenumab across multiple measures of impact, disability, and health-related quality of life. The observed treatment effects were similar in the non-medication overuse subgroup. CONCLUSIONS: Erenumab reduced migraine frequency and acute migraine-specific medication treatment days in patients with chronic migraine and medication overuse, improving disability and quality of life. CLINICALTRIALSGOV IDENTIFIER: NCT02066415. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that erenumab reduces monthly migraine days at 3 months in patients with chronic migraine and medication overuse.
引用
- Tepper SJ, Diener HC, Ashina M, et al. Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial. Neurology. 2019. PMID: 30996056. doi:10.1212/WNL.0000000000007497
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。